The hepatitis market outlook to 2016

857
-1

Published on

The report The Hepatitis Market Outlook to 2016 provides comprehensive coverage of the hepatitis market, incorporating a detailed epidemiological analysis. The report analyzes current leading brands, and profiles leading players in the hetpatitis market.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
857
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
10
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

The hepatitis market outlook to 2016

  1. 1. The Hepatitis Market Outlook to 2016Published:September 2011No.Of Pages:124Price:US $ 3835The report The Hepatitis Market Outlook to 2016 provides comprehensive coverage of thehepatitis market, incorporating a detailed epidemiological analysis. The report analyzescurrent leading brands, and profiles leading players in the hetpatitis market. It alsoidentifies products in late stage development and forecasts their expected salesperformance.Features and benefits* Understand how recent events are affecting the performance of major products, and howtheir marketers are confronting competitive market changes.* Compare the franchises of the leading companies in the hepatitis market, and understandhow the market share of these companies will change.* Evaluate pipeline compounds for the treatment of hepatitis and determine which productswill provide the greatest revenue growth.* Understand the market dynamics and interactions between the key drug classes used inthe treatment of hepatitis.* Forecast the performance of the leading marketed and pipeline products through to 2016.HighlightsThe launch of Incivek and Victrelis indicated for the treatment of hepatitis C, is anticipatedto change the treatment modality. The drugs are estimated to rapidly reach their peak salesby 2012-13 due to their superior therapeutic profile compared to the currently marketedproducts.A strong market opportunity exists in patients less responsive to current hepatitistreatment, including adults over 40 years of age, individuals with chronic renal disease andindividuals with HIV. The treatment-failure population, representing approximately 40% ofthe total hepatitis C infected population, also presents a significant opportunity.Roche was the global market leader in the treatment of hepatitis with a market share ofover 25%. Roches performance was driven by its hepatitis C products, Copegus andPegasys. These products represent the current standard of care in this indication where theycompete strongly with Pegintron and Rebetol of Merck and Co.Your key questions answered* Who were the leading players in the hepatitis market in 2010 and which products weredriving their performance?* What are the current market leading products in hepatitis treatment and how will theirmarket position change during the forecast period?
  2. 2. * Which of the seven major markets have the greatest market potential for hepatitistherapy?* How will the launch of Victrelis and Incivek impact upon the hepatitis C market?Table Of Contents* About the author o Disclaimer* EXECUTIVE SUMMARY o Overview and epidemiology of hepatitis o Global market analysis o Pipeline analysis o Competitive landscape* Overview and epidemiology of hepatitis o Summary o Introduction + Hepatitis A + Hepatitis B + Hepatitis C + Hepatitis D + Hepatitis E* Global market analysis o Summary o Introduction o Market analysis by country o Market analysis by drug class o Leading brand dynamics
  3. 3. + Pegasys (peginterferon alfa-2a) – Roche + Hepatitis Vaccines – GSK + Baraclude (entecavir) – BMS + PegIntron (peginterferon alfa-2b) – Merck + Viread (tenofovir disoproxil fumarate) – Gilead Sciences + Copegus (ribavirin) – Roche + Rebetol (ribavirin) – Merck + Hepsera (adefovir dipivoxil) – Gilead o A new era of treatment for Hepatitis C virus infection + Protease inhibitors (PIs) + The competition between Incivek and Victrelis + Factors governing the market space of Incivek and Victrelis + Product life cycle and forecast o Hepatitis market drivers, challenges, and resistors + Launch of novel drugs for HCV treatment will promote revenue sales growth + Increased awareness of hepatitis will create a short to medium term salesincrease + Challenges in bridging the treatment gap impedes forecast market uptake + Warehoused patients seeking new treatment options will temporarily createdemand + Drugs with reduced adverse effects change the treatment modality + Launch of biosimilars and generics will slow market growth + The WHO’s approval of the SFDA’s vaccine regulation will increase low costvaccine supply + Increasing HIV-HCV/HBV co-infection rates if not reduced will affect salesgrowth
  4. 4. o Key events + The FDA grants fast track status to Pharmasset’s PSI-7977 for the treatmentof HCV + Development program for therapeutic intranasal vaccine for treatment ofhepatitis B + Novartis discontinues the development of Joulferon/Zalbin on safety concerns + GSK signs microRNA deal with Regulus for HCV + Government initiatives to curb the incidence of hepatitis + Vertex collaborates with Alios for hepatitis portfolio o Biosimilars and generics o Leading hepatitis drugs sales forecast* Pipeline analysis o Summary o Introduction o Key trends in hepatitis R&D + Product differentiation will hold the key to success in the hepatitis market + Multi-billion dollar opportunity for a successful drug class + The treatment-failure population presents a significant opportunity + End stage renal disease (ESRD) patients present high potential for vaccines + Despite the introduction of novel treatments, the SOC for hepatitis C will notchange o Profiles of the key pipeline products + TMC435 – Medivir/J&J + BI 201335 – Boehringer Ingelheim + Vaniprevir (MK-7009) – Merck
  5. 5. + Debio 025 – Novartis/Debiopharm + Danoprevir (ITMN-191/RG7227) – Roche + RG-7128 – Roche/ Pharmasset + ABT-450 – Abbott/Enanta + BMS-790052 – Bristol-Myers Squibb + GS-9190 (Tegobuvir) – Gilead Sciences + GS-9256 – Gilead Sciences + ACH-1625 – Achillion* Competitive landscape o Summary o Introduction o Competitive positioning of the leading players in the global hepatitis market o Roche + Marketed product portfolio + Pipeline analysis + Strategic and growth analysis o GSK + Marketed product portfolio + Pipeline analysis + Strategic and growth analysis o Merck & Co. + Marketed product portfolio + Pipeline analysis + Strategic and growth analysis
  6. 6. o Gilead + Marketed product portfolio + Pipeline analysis + Strategic and growth analysis o Bristol-Myers Squibb + Marketed product portfolio + Pipeline analysis + Strategic and growth analysis* Appendix o Scope o Methodology + Epidemiology + Market forecast o Glossary/Abbreviations + Abbreviations o Bibliography/References* TABLES o Table: Worldwide endemicity of HAV infection o Table: Segmentation of regions by prevalence of hepatitis B o Table: Prevalence of hepatitis B by country o Table: Forecast epidemiology of chronic hepatitis B to 2016 o Table: Prevalence of hepatitis C infection by country o Table: Forecast epidemiology of hepatitis C in the 7MM to 2016 o Table: Global hepatitis market by region ($m), 2010
  7. 7. o Table: Hepatitis market by drug class ($m), 2010o Table: Leading brands in the global hepatitis market ($m), 2010o Table: Result of SPRINT-2 clinical trial in different cohortso Table: Efficacy comparison of Incivek and Victrelis in Phase III studyo Table: Forecast sales of Incivek and Victrelis, 2010-16o Table: Impact of drivers and challenges in hepatitis market to 2016o Table: Adverse effects associated with different treatment modalitieso Table: Leading hepatitis brands sale forecast ($m), 2010-16o Table: An overview of TMC435o Table: An overview of BI 201335o Table: An overview of vanipreviro Table: An overview of Debio 025o Table: An overview of danopreviro Table: An overview of RG7128o Table: An overview of ABT-450o Table: An overview of BMS-790052o Table: An overview of GS-9190o Table: An overview of GS-9256o Table: An overview of ACH-1625o Table: Leading players in the global hepatitis market ($m), 2010o Table: Performance of Roches hepatitis products ($m), 2010o Table: Roche’s hepatitis R&D pipeline, April 2011o Table: Performance of GSKs hepatitis products ($m), 2010o Table: GSK’s hepatitis R&D pipeline, Feb 2011
  8. 8. o Table: Performance of Mercks hepatitis products ($m), 2010 o Table: Merck’s hepatitis R&D pipeline, Feb 2011 o Table: Performance of Gileads hepatitis products ($m), 2010 o Table: Gilead’s hepatitis R&D pipeline, Feb 2011 o Table: Performance of BMS’ hepatitis products ($m), 2010 o Table: BMS’ hepatitis R&D pipeline, Feb 2011* FIGURES o Figure: Evolution of HCV treatment modalities o Figure: Perceptual position of Incivek and Victrelis o Figure: Competitive position of Incivek and Victrelis o Figure: Product life cycle of Incivek and Victrelis o Figure: Forecast sales of Incivek and Victrelis to 2016 o Figure: Sales of the leading players in the global hepatitis market ($m), 2006-2010 o Figure: Response of patients to drug therapyAbout Us:ReportsnReports is an online library of over 100,000+ market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit our Market Research Blog

×